Welcome to our dedicated page for Pacira Biosciences news (Ticker: PCRX), a resource for investors and traders seeking the latest updates and insights on Pacira Biosciences stock.
Pacira BioSciences, Inc. (Nasdaq: PCRX) is a pioneering company dedicated to advancing non-opioid pain management and regenerative health solutions. Headquartered in Tampa, Florida, Pacira is committed to providing innovative treatments that minimize the reliance on opioids for pain relief, thereby redefining the role of opioids as a rescue therapy only.
Pacira has three primary commercialized products: EXPAREL® (bupivacaine liposome injectable suspension), ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), and ioveraº®. EXPAREL, launched in 2012, is a long-acting local analgesic used for postsurgical pain management, offering significant reductions in opioid consumption and cumulative pain scores. ZILRETTA, approved in 2017, is an extended-release intra-articular injection aimed at managing osteoarthritis knee pain, providing extended pain relief without repeated administration. ioveraº is a novel handheld device that delivers precise, controlled doses of cold temperature to targeted nerves, offering immediate, drug-free pain relief.
The company’s advanced DepoFoam® delivery platform encapsulates drugs in a multivesicular liposome, releasing them over extended periods without altering their molecular structure. This technology underpins the efficacy of Pacira’s flagship product, EXPAREL, which has been pivotal in reducing opioid use and enhancing postoperative recovery.
Pacira continues to innovate with ongoing clinical developments and strategic initiatives. Recently, the company reported preliminary unaudited total revenue of $675.0 million for the fiscal year 2023. In 2024, Pacira plans to launch EXPAREL for two key lower extremity nerve blocks and anticipates the rollout of the NOPAIN Act in 2025, which will expand patient access to opioid-sparing pain management solutions.
Pacira’s commitment to developing non-opioid treatments is further demonstrated by its recent achievements in securing FDA and European Medicines Agency designations for PCRX-201, a gene therapy product candidate for osteoarthritis. The company’s focus on long-term growth and operational excellence remains steadfast under the leadership of CEO Frank D. Lee.
For more information on Pacira BioSciences and its product offerings, visit www.pacira.com.
Pacira BioSciences, Inc. (NASDAQ:PCRX) will report its first quarter financial results on May 3, 2023, before U.S. market opening. A conference call is scheduled for 8:30 a.m. ET the same day. Participants may pre-register for Q&A via telephone to receive dial-in details. The event will also be available as a live webcast. Pacira focuses on non-opioid pain management solutions and offers three commercial products: EXPAREL®, ZILRETTA®, and ioveraº®. These innovative interventions aim to reduce dependence on opioids and address various pain-related conditions.
Pacira BioSciences, Inc. has partnered with the Invited Celebrity Classic, a PGA TOUR Champions event, to promote non-opioid pain management using its device, iovera°. The device applies targeted cold therapy to alleviate chronic and acute pain without medications. Paul Goydos, a professional golfer, joins as a brand ambassador to raise awareness of iovera°.
The partnership includes on-site activations and education at various golf tournaments throughout the year, with the inaugural event occurring from April 21-23, 2023, at the Las Colinas Country Club. This initiative aims to highlight the benefits of non-opioid options and reduce reliance on opioid medications, which carry substantial addiction risks. Pacira currently focuses on redefining pain management through innovation.
Pacira BioSciences, Inc. (NASDAQ: PCRX) announced the appointment of Christopher Young as Chief Manufacturing Officer on April 19, 2023. Young, a seasoned operations executive, will oversee all manufacturing activities for Pacira's product portfolio, focusing on supply chain design, product life cycle management, and global product launches. Prior to joining Pacira, he held senior roles at Akorn Inc. and Alvogen Inc., demonstrating a strong track record in operational leadership and efficiency improvements. CEO Dave Stack praised Young for his team-building skills and operational expertise. Young expressed enthusiasm for contributing to Pacira's vision of providing opioid alternatives and enhancing patient care.
FAQ
What is the current stock price of Pacira Biosciences (PCRX)?
What is the market cap of Pacira Biosciences (PCRX)?
What is Pacira BioSciences, Inc. known for?
What are Pacira BioSciences' main products?
What is EXPAREL used for?
What recent financial milestone did Pacira achieve?
What is ZILRETTA?
How does ioveraº work?
What is the DepoFoam® delivery platform?
What are Pacira’s plans for 2024?
What is PCRX-201?
Where can I learn more about Pacira BioSciences?
